We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Additional Patent Rights definition

Additional Patent Rights means Board’s rights in inventions or discoveries covered by patent(s) or patent applications, whether domestic or foreign, within the Licensed Field resulting and constituting an Improvement.
Additional Patent Rights means GENERAL’s rights in *** and any other divisional or continuation patent applications naming one or more GENERAL employees as inventors to the extent the aforementioned are jointly owned with PALOMAR. ADDITIONAL PATENT RIGHTS shall also include those claims in any continuation-in-part of the aforementioned patent applications which claim an invention described or claimed in the above listed original filings to the extent the aforementioned are jointly owned with PALOMAR. ADDITIONAL PATENT RIGHTS shall also include future Joint Inventions arising under the Joint Patent Agreement for which PALOMAR elects to obtain an exclusive license under Section 3 thereof.
Additional Patent Rights means all Patent Rights, other than the Regents’ Patent Rights, that are Controlled by The Regents during the term of the License Agreement that satisfy all of the following criteria: (a) the practice, manufacture, use or sale of the invention in such Patent Right is covered or claimed by a claim in The Regents Patent Rights; (b) the invention arose from Investigator’s Laboratory Work; (c) the invention was conceived of and reduced to practice (solely or jointly with others) prior to the Effective Date or on or after the Effective Date but prior to the 24-month anniversary of the Sixth Amendment Effective Date; (d) covers the use of Compounds in the Field of Use.

Examples of Additional Patent Rights in a sentence

  • If PLx notifies Board that it does not intend to pay the costs of an application, or if PLx does not respond or make an effort to agree with Board on the disposition of rights in the subject invention, then Board may file an application at its own expense, such invention shall not be included in Patent Rights or Additional Patent Rights for the purposes of this Agreement, and PLx will have no rights to such invention.

  • UTHSC-H will invoice PLx for all actual out-of-pocket expenses incurred by UTHSC-H for filing, prosecuting, enforcing and maintaining Patent Rights and Additional Patent Rights.

  • In addition to any royalties payable by us to Alnylam pursuant to the terms of the Amended and Restated License and Collaboration Agreement, we agreed to pay Alnylam an additional low single-digit royalty on net sales of certain products utilizing the Additional Patent Rights, with the exact royalty percentage payable being dependent on the total amount of net sales during the calendar year.

  • Any questions, claims, disputes, remedies or procedural matters shall be governed by the laws of the State of Delaware and of the United States of America, without regard to its principles of conflicts of law; provided, that those matters pertaining to the validity or enforceability of the Patent Rights and Additional Patent Rights shall be interpreted and enforced in accordance with the laws of the territory in which such Patent Rights exist.

  • Licensor and its Affiliates hereby grant to Licensee and its Affiliates, under Licensor’s and its Affiliates’ entire right, title and interest in and to the Additional Patent Rights, a worldwide, non-exclusive, royalty-free, fully paid up, non-transferable (except in accordance with Section 10.9), non-sublicensable license to make, have made, use, sell, offer to sell, have sold and import Permitted Products in the Field of Use.


More Definitions of Additional Patent Rights

Additional Patent RightsFor clarity, Additional Patent Rights are a subset of Harvard Patent Rights.
Additional Patent Rights means the Patent Rights listed on Exhibit B.
Additional Patent Rights means: (a) The U.S. and non-U.S. patents and patent applications listed in Exhibit B; (b) U.S. and non-U.S. patents that issue from or claim priority to any patent or patent application listed in Exhibit B, U.S. and non-U.S. patent applications that claim priority to any patent or patent application in Exhibit B, but not including claims in continuation-in-part applications or patents except to the extent provided in (c) below; (c) Claims in continuation-in-part applications or patents described in (b) above to the extent that such claims are entitled to priority to patents or patent applications listed in Exhibit B; and [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Table of Contents (d) Any reissues, re-examinations, or term extensions of patents described in (a), (b), or (c) above.
Additional Patent Rights means each claim of patents and each claim of patent applications, other than the Patent Rights, wherein such patents or patent applications are
Additional Patent Rights means any United States patents that shall issue to Biogen from the following patent applications or any divisional, continuation, continuation-in-part, continuing prosecution application, reissue, renewal or extension thereof or substitute therefor:[xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxx]; however, U.S. Seriax Xx. 000, 00 0, xxxxx Xxrch 3, 1983 is excluded from this definition.
Additional Patent Rights means each claim of patents and each claim of patent applications, other than the Patent Rights, wherein such patents or patent applications are owned by Licensor and/or its Affiliates as of the Effective Date, and also including (i) all continuing applications of such patents and patent applications including continuations, continuations in part, divisions and substitutions; (ii) any patents issuing on any of the foregoing, including all reexaminations, reissues, and extensions; (iii) all foreign patent applications and patents corresponding to any of the foregoing, and (iv) any patents or patent applications claiming priority to any of the foregoing, but in each case (i.e., of (i), (ii), (iii), and (iv)) only to the extent that such patents Cover (in the case of such patents) or would Cover (in the case of such patent applications), all solely within the Field of Use, the following: (a) Licensee’s t:slim® Insulin Delivery System, [***], and its designs, and (b) the following additional products and their designs that are owned and in development by Licensee [***]: A. therapy management software (“t:ConnectTM”); B. an insulin delivery system including a pump with an enhanced capacity for delivering larger quantities of insulin (e.g., 500 units) relative to the t:slim® Insulin Delivery System (“t:flex™”); C. an insulin delivery system including a pump having two or more xxxxxxxx for delivering one or more additional types of medicament in addition to insulin (“t:dual™”); and D. an insulin delivery system including a pump and an accompanying but separate (remote) control unit (t:sport™); ((a) and (b) collectively, the “Permitted Products”). Licensee’s trademarks T:CONNECT, T:FLEX, T:DUAL and T:SPORT listed above (the “New Product Trademarks”) are understood by the Parties only to be references to the described products and designs still under development for which they are listed as of the Effective Date. The New Product Trademarks are not meant to limit in any way the substantive elements of the products and designs for which they are listed. Any or all of the New Product Trademarks may be changed by Licensee in its sole judgment at any time without removing such products and designs from Additional Patent Rights. Licensee agrees to notify Licensor if any of the New Product Trademarks are replaced or materially modified.
Additional Patent Rights means all rights in, to or under any patent application or patent not under the Control of CRI, CHOP, TGC, or IAVI which are [*] for the Development, Manufacture and/or Commercialization of any IAVI Vaccine or TGC Vaccine as the case may be, by the applicable Party or Parties.